Screener
Crinetics Pharmaceuticals CRNX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Cash, cash equivalents and restricted cash - end of period | $115,141 | $95,869 |
| COMPONENTS OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH | ||
| Cash and cash equivalents | $114,341 | $94,569 |
| Restricted cash | 800 | 1,300 |
| Cash, cash equivalents and restricted cash at end of period | $115,141 | $95,869 |
| NONCASH INVESTING AND FINANCING ACTIVITIES | ||
| Stock options exercised receivable | $3 | $15 |
| Amounts accrued for purchases of property and equipment | $464 | $264 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's restricted cash?
- Crinetics Pharmaceuticals (CRNX) reported restricted cash of $800K in Q1 2026.
- How has Crinetics Pharmaceuticals's restricted cash changed year-over-year?
- Crinetics Pharmaceuticals's restricted cash increased by 60.0% year-over-year, from $500K to $800K.
- What is the long-term trend for Crinetics Pharmaceuticals's restricted cash?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $500K to $0.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Crinetics Pharmaceuticals's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude